Jones Financial Companies Lllp Purchases 11,045 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Jones Financial Companies Lllp grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 205,829 shares of the medical equipment provider’s stock after buying an additional 11,045 shares during the period. Jones Financial Companies Lllp owned 0.10% of Zimmer Biomet worth $20,221,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Zimmer Biomet by 0.9% in the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock valued at $2,120,751,000 after acquiring an additional 198,370 shares during the last quarter. Dodge & Cox lifted its position in Zimmer Biomet by 12.9% during the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after purchasing an additional 2,533,009 shares during the period. American Century Companies Inc. boosted its stake in shares of Zimmer Biomet by 8.7% in the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after purchasing an additional 458,903 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Zimmer Biomet by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after purchasing an additional 69,485 shares during the last quarter. Finally, Primecap Management Co. CA grew its position in shares of Zimmer Biomet by 0.6% during the 2nd quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock worth $429,675,000 after buying an additional 27,860 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH stock opened at $86.15 on Wednesday. Zimmer Biomet Holdings, Inc. has a 1-year low of $84.59 and a 1-year high of $114.44. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. The firm has a market cap of $17.07 billion, a PE ratio of 21.32, a P/E/G ratio of 2.20 and a beta of 0.62. The business’s 50-day moving average price is $90.64 and its two-hundred day moving average price is $95.87.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same quarter last year, the firm posted $1.74 earnings per share. Zimmer Biomet’s revenue was up 9.6% compared to the same quarter last year. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s payout ratio is presently 23.76%.

Analyst Upgrades and Downgrades

ZBH has been the topic of several analyst reports. Robert W. Baird restated a “neutral” rating and issued a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $100.00 target price (down previously from $115.00) on shares of Zimmer Biomet in a research report on Thursday, November 6th. Sanford C. Bernstein increased their price target on Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research note on Friday, January 9th. UBS Group reduced their price target on Zimmer Biomet from $88.00 to $86.00 and set a “sell” rating on the stock in a research report on Wednesday, January 28th. Finally, Canaccord Genuity Group dropped their price objective on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $107.24.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.